Lixisenatide Arterial Stiffness Trial (LAST) Version 3.0
Research type
Research Study
Full title
Effect of Lixisenatide on arterial stiffness in patients with diabetic nephropathy
IRAS ID
209757
Contact name
Janaka Karalliedde
Contact email
Sponsor organisation
King's College London
Eudract number
2016-001758-17
Duration of Study in the UK
3 years, 0 months, 0 days
Research summary
Diabetic kidney disease (DKD) develops in nearly 40% of patients with type 2 diabetes (T2DM) and is the leading cause of renal disease in the UK. Patients with DKD are at higher risk of cardiovascular disease (CVD). Increased arterial stiffness due to loss of elasticity of the blood vessels and the presence of protein (albumin) in the urine can predict future risk of CVD and progression of DKD. Glucagon receptor agonists (GLP-1) are an approved treatment for T2DM. These drugs appear to have potential CVD benefits. However the exact mechanisms for these effects remain unclear. GLP-1 receptor agonists may improve the health of arteries by reducing arterial stiffness and the amount of albumin in the urine. Lixisenatide is a GLP-1 receptor agonist that is licensed for the treatment of adults with T2DM in the UK. The purpose of this study is to measure the effect of Lixisenatide on arterial stiffness in patients with diabetic kidney disease. If Lixisenatide can reduce arterial stiffness and other predictors of CVD, this work would enable us to get important information to perform a larger trial to see if this treatment reduces the risk of end stage renal disease and CVD in patients with DKD.\n
REC name
London - Bloomsbury Research Ethics Committee
REC reference
16/LO/1947
Date of REC Opinion
14 Nov 2016
REC opinion
Favourable Opinion